The role of radiotherapy in multimodal treatment of pancreatic carcinoma

Table 3 Selected studies for locally advanced pancreatic cancer employing chemoradiation ± chemotherapy

Trial (patients)	Chemotherapy*	Radiotherapy (Gray)	Median survival (months)	p-value
Johnson[59] (129)	Lithium Gamonelate	-	5.4	n.a.
Maisey[56] (44/46)	5/FU PVI 5-FU/MMC	-	32% 1 year 43% 1 year	n.a.
Louvet[60] (47/50)	Gem Gem/Ox	- -^$	10.3 10.3	p = n.s.
Rocha Lima[61] (24/27)	Gem Gem/Iri	- -^$	11.7 9.8	p = n.s.
Van Cutsem[62] (80/82)	Gem Gem/tipifarnib	-	8.7 11	p = n.s.
GITSG 1985[77] (25/83/86)	- *5-FU* *5-FU*	60 40 60	5.2 9.6 9.2	p < 0.01
GITSG 1988[50] (24/24)	*SMF* SMF	54 -	6.5 5.1	p < 0.02
Klaassen[52] (44/47)	*5-FU* 5-FU	40 -	8.3 8.2	n.a.
Chauffert[53] (59/60)	*5-FU(PVI)/Cis*+Gem Gem	60 -	8.0 14.5	p = 0.03
Loehrer[55] (36/38)	*Gem*+ Gem Gem	50.4 -	11.0 9.2	p = 0.034
Crane[66] (53/61)	*Gem* *5-FU*(PVI)	30 (10#)	11 9	p = n.s.
Li[78] (18/16)	*Gem* *5-FU*	50.4	14.5 6.7	p = 0.027
Ishii[63] (20)	*5-FU*(PVI)	50.4	10.3	n.a.
McGinn[65] (37)	*Gem*	24-42	11.6	n.a.
Shinchi[47] (16/15)	*5-FU*(PVI) Supportive care	50.4 -	13.2 6.4	n.a.
Brunner[67] (40/42)	*Gem/Cis+ Gem Gem/Cis*	55.8 55.8	13 8	p < 0.0001
Huguet[24] (72/56)	*5-FU*(PVI)+ as below FolFuGem, GemOx	55 -	15 11.7	p = 0.0009
Kachnic[64] (23)	*5-FU*+ Gem	50.4	13	n.a.

*: bold and italics indicate chemotherapy given as concurrent chemoradiotherapy #: radiotherapy fraction number; ^$: a chemotherapy only trial, but very few patients had some radiotherapy; 5-FU: 5-fluorouracil bolus injection unless marked as 'PVI'; Cis: cisplatin; Gem: gemcitabine; Fol: folinic acid; Iri: irinotecan; MMC: mitomycin C; n.a.: not available; n.s.: not significant; Ox: oxaliplatine; PVI: protracted venous infusion, SMF: streptozotocin, mitomycin, 5-fluorouracil.